I Sat In The FDA Trial Meeting While My Boss Used My Name To Cover Deleted Consent Violations And Then The FDA Director Walked In

I Sat In The FDA Trial Meeting While My Boss Used My Name To Cover Deleted Consent Violations And Then The FDA Director Walked In

My name is Irena Mirescu. I am the clinical trial quality assurance lead for the pivotal Phase 3 program at this CRO. I have spent six years building the credibility my quarterly QA report carries with the FDA BIMO inspector – and Patrice Navarrete has spent those same six years using my signature as the reason no one looked twice at the 23:05 Friday eTMF compactor.

The central-lab record was open on my left monitor. The site notes and medical history occupied the right. I cross-referenced the subject-eligibility flag for a low-enrolling Phase 2 study. The participant’s creatinine clearance had trended out of the protocol window during week six. A clinical research coordinator had escalated the flag to my queue on a Tuesday morning, asking for a protocol deviation ruling.

I checked the trend against the protocol’s monitoring tolerance framework. The site had followed the dose-modification rule exactly as written. They had not violated the protocol. They had documented a physiological shift.

I opened a blank advisory document. I typed my assessment. “No protocol deviation; recommend medical monitor advisory document the trend for safety reporting.”

I reviewed the sentence. The project manager had asked me twice that week to find a way to keep the site’s deviation metric green without triggering a medical monitor review. A medical monitor review required a formal sponsor notification. I did not delete the recommendation. I did not soften the language. I attached the lab PDF. I clicked send. I closed the window and pulled the next file.

Six months later, the projector fan hummed above the podium in a hotel ballroom in Chicago. I stood before sixty attendees at the Society of Quality Assurance annual meeting. My title slide read: ‘Reading the eTMF Audit Trail: Where Consent Lives.’

I clicked the presenter remote. The screen split into two columns. On the left, a standard monitoring report. On the right, a purged one. I showed the audience identical site-visit summaries. Then I advanced to the next slide, revealing the underlying electronic Trial Master File audit trails beneath both reports. The metadata hashes did not match. The visual difference was a single line of alphanumeric code.

A junior auditor in the third row raised her hand. She leaned forward to the aisle microphone. “Can you tell from the monitoring report alone if deviations have been removed?”

I looked at the microphone stand. I looked at the auditor.

“Most of the time, yes,” I said. “The eTMF audit trail is what gives it away.”

I pressed the remote. The slide advanced to a full-screen display of a deletion timestamp. The room was quiet. Nobody asked a follow-up question. I finished the hour.

Three years ago, the CRO completed its first FDA Bioresearch Monitoring inspection. We had zero findings on the predecessor Phase 2 study. The company ordered catered lunch and gathered seventy employees in the main conference room for a quality celebration.

Patrice Navarrete stood at the front of the room. She was the CRO operations director. She held a black frame with a white matting.

She called my name. I walked to the front of the room. She handed me the frame. It held a copy of the FDA inspection report.

“The agency cited your QA work as the cleanest monitoring oversight in the company,” Patrice said. She looked at the crowd. She looked at me. “Thank you, Irena.”

She called me by my first name. I took the frame. I shook her hand. I believed her. The next morning, I drove a nail into the wall above my office credenza and hung the frame. It stayed there.

My credenza held a row of eight white three-ring binders. One for each quarter of the Phase 3 program. I used a black marker to write the labels on the spines. The QA – Phase 3 Q3 binder sat directly below the framed BIMO letter.

During a vendor audit, a new compliance officer asked why I maintained physical archives when the sponsor mandated a digital-first governance model.

I pulled a binder from the shelf. I set it on the desk. “An eTMF audit trail does not edit itself,” I told him. “That is why I still print the quarter-end.”

I walked past those eight binders every morning for two years. I reached past the Q3 binder to grab the Q4 binder for a separate review. They were heavy. They meant the sites were monitored, the reports were signed, and the data was archived. They meant nothing else. Not yet.

Six weeks ago, an email arrived from Bonnie Pryor, my lead site monitor.

“I logged a consent-witness-only deviation on a cognitively-impaired participant on Friday afternoon,” Bonnie wrote. “The eTMF shows nothing in the audit trail Saturday morning. Probably eTMF latency, but flagging.”

I read the email on my phone in the parking lot. I unlocked my car. I typed a response with my thumb.

“Will check the audit trail – thanks Bonnie.”

I filed the email in a subfolder. I started the engine. I did not check.

The CRO headquarters was mostly empty by nine o’clock on Friday night. The HVAC system had dropped to its weekend cycle, leaving the third floor quiet except for the hum of the server room down the hall. I sat at my desk to run the routine quarter-end quality assurance reconciliation.

I arranged my three monitors. On the left screen, I opened my email archive and found the message Bonnie Pryor had sent six weeks earlier. On the right screen, I loaded the scanned PDFs of the site-visit notes my monitors had uploaded from the field. On the center screen, I opened the electronic Trial Master File viewer.

I set the parameters for the Atlanta site. I pulled the record for Subject 4-117.

A site-visit note is a static document. A PDF is just a picture of an event. But an eTMF audit trail is a 21 CFR Part 11 compliant hash chain. It records every keystroke, every entry, every modification, and every deletion. It stamps them with a user ID and a time down to the second.

I looked at the right screen. Bonnie’s contemporaneous note, signed and uploaded on a Friday afternoon, logged a clear protocol deviation for Subject 4-117. A consent form had been witnessed, but not signed by the participant. The participant had documented cognitive impairment.

I looked at the center screen. I scrolled through the eTMF audit trail hashes for that same Friday.

At 16:41, the audit trail showed Bonnie’s user ID creating the deviation entry.At 23:08, the audit trail showed a new entry.The deviation was deleted.The user ID attached to the deletion was not Bonnie. It was not a site coordinator. It read: System Maintenance.

I stopped scrolling.

I closed the Atlanta site folder. I opened the master query tool for the entire Phase 3 program. I set the filter for informed-consent deviations. I set the secondary filter for deletion events. I hit run.

The progress bar filled the center screen. The query took four minutes to process the global database.

The results populated in a spreadsheet matrix.

Eighty-seven informed-consent deviations.Eighty-seven deletions.Four sites. The four highest-enrolling sites in the pivotal Phase 3 trial.

I highlighted the timestamp column. Every single deletion occurred on a Friday night. The window was absolute. The earliest deletion was 23:05. The latest was 23:30.

The sponsor’s data review governance committee met on Saturday mornings.

Fourteen of the deleted deviations involved participants with cognitive impairment.

System maintenance does not evaluate cognitive impairment. System maintenance does not isolate high-enrolling sites. System maintenance does not clean a database thirty minutes before a sponsor review.

I saved the export. I opened an encrypted drive. I dragged the file across the screen.

Eleven months ago, Charlene Booker resigned without notice.

She had been my senior monitor for the Eastern seaboard. She was methodical, rigorous, and completely unbothered by site pushback. On a Wednesday afternoon, human resources sent a building-wide automated email stating her access badge had been deactivated.

I took the elevator down to the lobby. Charlene was carrying a single cardboard box through the revolving glass doors.

I followed her outside. The heat off the asphalt was intense. We walked to her car in silence. She set the box on the trunk of her sedan. She did not look at the building.

“Did Patrice fire you?” I asked.

Charlene pulled her keys from her purse. She reached into her jacket pocket. She pulled out a manila site-visit folder cover, folded in half. She handed it to me.

“Pull the eTMF audit trail against my site notes,” Charlene said.

She opened her car door. She slid into the driver’s seat. She pulled the door shut, started the engine, and drove toward the exit gate.

I stood in the parking lot. I looked at the folded manila cover. A phone number was written on the inside flap in blue ink. I brought it back to my office. I put it in the bottom left drawer of my desk. I locked the drawer. I never pulled the audit trail. I trusted the quarterly reports Patrice signed and handed back to me.

I pushed my chair away from the center monitor. I unlocked the bottom left drawer.

I moved a stack of blank vendor forms. The folded manila cover was underneath.

I picked up my personal cell phone. I typed the number written in blue ink. I drafted a new message.

I am pulling the eTMF audit trail now.

I sent the text. I set the phone face up on the desk.

I stood up. I walked to the breakroom at the end of the hall. I filled a paper cup with water from the cooler. I drank it. I threw the cup away. I walked back to my office. I sat down.

The screen of my phone illuminated. Forty minutes had passed.

Eight months, the text from Charlene read. Patrice told us delete on the Friday compactor or lose the database-lock bonus pool. I will testify.

I opened the white QA – Phase 3 Q3 binder sitting on my desk. I turned to the August tab. I took a pen. I wrote inside the front cover of the tab section: C. Booker – witness available.

The binder lay open beneath the overhead fluorescent light. It was no longer an archive.

I peeled a yellow sticky note from the dispenser. I wrote: 23:08 Friday delete – Subject 4-117 consent-witness-only.

I pressed the sticky note onto the August page. It adhered directly above the final signature block. The signature block read: QA report: monitoring activities effective.

The handwriting on the signature line was mine.

I had signed that page. I had signed the July page. I had signed every page for eight quarters. I had certified that the sites were compliant, the deviations were managed, and the clinical practice was sound. I had built a career on the absolute integrity of my oversight.

Patrice Navarrete viewed informed-consent deviations as a protocol-compliance variation. In her operational framework, missing signatures on witnessed consents were administrative-completeness issues. They were messy. They triggered sponsor audits. They delayed database locks. They threatened the multi-million-dollar performance bonuses tied to trial completion.

She did not alter the site-visit PDFs. That would be forgery. She used the generic system maintenance login to purge the hash chain at 23:05, removing the administrative friction before the sponsor ever saw the Saturday dashboard. She left the physical notes alone, knowing no one ever compared the static PDF to the live hash chain.

She knew I only reviewed the quarterly summaries she approved as designated quality officer. She knew I trusted the system.

I looked at the framed FDA BIMO inspection letter hanging on the wall above my credenza. The agency had cited my oversight as the cleanest in the company. Patrice had handed me that frame in front of seventy people.

My clean oversight was not a standard. It was her shield.

Earlier that afternoon, Patrice had emailed me a PDF of the sponsor governance committee binder. The committee was scheduled to meet before the pivotal data lock.

I opened the PDF on my left monitor. I scrolled past the enrollment metrics. I scrolled past the safety adverse-event summaries. I stopped on slide 5.

The header read: Monitoring Oversight Verification – Prior-Period QA.

The center of the slide featured a single bullet point. It listed my name. It listed my clinical quality assurance certification number.

I had not authorized the slide. I had not been asked for my consent. The binder was designed to show the sponsor’s Chief Medical Officer and the Institutional Review Board that the trial’s monitoring oversight was entirely independent of Patrice’s operational team.

She was going to put my name on the screen to validate eighty-seven deleted deviations.

I closed the eTMF audit-trail viewer.

I copied the eight-month spreadsheet export to my personal encrypted drive. I copied Bonnie Pryor’s six-week-old email. I copied the site-visit PDF for Subject 4-117.

I picked up my phone. I opened the camera. I held the lens steady over the open white Q3 binder. I photographed the August tab, the sticky note, and my own signature on the effectiveness report.

I opened a new browser window. I navigated to the FDA Bioresearch Monitoring (BIMO) complaint intake portal.

I did not click start immediately. I clicked on the regulatory guidelines tab. I read the form instructions from beginning to end. I read the definitions of whistleblower protection, the scope of 21 CFR Part 11 violations, and the parameters for a for-cause inspection trigger.

I looked at the clock in the bottom corner of my screen. It was 10:11 PM.

I did not call Patrice Navarrete. I did not draft an email to the CRO General Counsel. The General Counsel sat on the sponsor governance committee.

I clicked the button to open a new intake form.

I placed my hands on the keyboard. I typed my name. I typed my credential number. I typed the trial protocol designation. I attached the eight-month eTMF audit-trail export. I attached it a second time to ensure the upload registered. I attached the site-visit PDFs. I attached the screenshot of the 23:08 deletion timestamp.

I typed slowly. The office was completely silent.

The office was starting to fill on Tuesday morning. I sat at my desk and watched the traffic back up on the interstate through the window. The ambient noise of the clinical operations floor rose as the monitors arrived and logged into their workstations. My inbox chimed.

An email arrived at 7:25 AM. The sender was Patrice Navarrete. The subject line read: Sponsor Governance Committee – Presenter Addition.

I opened the message. There was a PDF attachment of the revised meeting agenda.

“The CMO always asks about QA independence,” Patrice’s cover note read. “I’ve added you as a co-presenter for the monitoring oversight verification section. Wednesday afternoon, twenty-five minutes.”

I looked at the digital calendar in the corner of my screen. The governance committee meeting was exactly nine days away. In nine days, Patrice expected me to sit next to her at a long oak table and validate the purged compliance records directly to the sponsor’s Chief Medical Officer.

I had nine days to either become an active participant in a federal fraud, or ensure the FDA Bioresearch Monitoring complaint landed first.

I placed my hand flat on the desk. I closed the email. I did not reply to confirm my attendance.

For three years, I had watched Patrice manage the clinical operations floor. I had seen the site-compliance metrics always land perfectly in the green by Saturday morning. I chose to believe it was efficiency. I had watched the high turnover rate among the senior field monitors. I chose to believe it was standard industry attrition.

I had noticed how she never asked for the underlying site-visit PDFs during audit preparation, only the aggregated summary tables. I chose to believe she implicitly trusted my oversight.

I had built a career on identifying the exact moments where clinical execution deviated from the protocol, but I had spent thirty-six months ignoring the structural perfection of my own department. I had let my signature become a mechanism for her convenience because she handed me a framed letter and called me the cleanest QA lead in the company.

I left the office at five o’clock. I drove to a townhouse in the eastern suburbs.

Charlene Booker opened her front door before I could knock. She led me to her dining room. I set my laptop and a portable printer on the wood table. We sat across from each other.

She did not ask for small talk. She dictated the timeline of her resignation. She named the dates. She named the site codes.

“Patrice called the senior monitors into a closed-door meeting in January,” Charlene said. I typed her words as she spoke them. “She told us the pivotal database lock was the only metric the board cared about. She told us that if we did not clean up the administrative friction on the Friday compactor, we would lose the entire database-lock bonus pool. When I refused to delete a consent deviation, she removed my system access.”

I printed the document. The printer whirred loudly in the quiet dining room. I slid the single sheet of paper across the table.

Charlene picked up a black pen. She signed the affidavit. She pushed it back to me.

I folded the paper in half. I put it in my bag. I drove home in the dark.

My kitchen was entirely dark the next morning except for the glow of my laptop screen. It was 6:44 AM. The FDA BIMO complaint intake portal was live on the display.

I did not wait for the committee. I did not ask for a meeting with the CRO executive board. The executives were compensated by the same bonus pool.

I clicked the upload button.

I attached the hash-anchored eight-month eTMF audit-trail export. I attached the PDF of the monitor site-visit notes. I attached the spreadsheet listing all eighty-seven deletion events. I attached Bonnie Pryor’s six-week-old email. Finally, I attached the scanned PDF of Charlene Booker’s sworn affidavit.

I scrolled to the bottom of the form. I checked the box certifying the submission under penalty of perjury.

I pressed the enter key. I pushed the laptop back an inch.

The portal processed the files. A confirmation screen appeared, generating a confidential case number: BIMO-4481-C.

Later that afternoon, I walked past the executive suite at the CRO. Patrice’s office had floor-to-ceiling glass walls. The blinds were fully open.

I stopped near the copy machine. I could see her clearly. She had the sponsor CMO on speakerphone, finalizing the committee binder. She was completely calm. She leaned back in her ergonomic chair, looking out across the floor toward the eTMF workstations.

The database lock was scheduled for the Friday after the committee meeting. The multi-million-dollar program-completion bonus was secure. The 23:05 Friday compactor cycle was running automatically.

“Keep slide five verbatim,” Patrice said. Her voice carried through the open door into the hallway. “Governance committees read the QA lead’s name first. It establishes the baseline.”

An office administrator walked past the door carrying a stack of files. Patrice flagged her down without muting the phone.

“Add Irena Mirescu, certified clinical QA lead, to the presenter bio,” Patrice told her.

She did not lower her voice. She named my credential to the administrative staff as a marketing asset. She had not asked for my consent. She turned back to her desk and closed her door.

I kept walking toward the breakroom.

The secondary tension of the timeline was not resolved. The FDA BIMO portal had generated a case number, but the agency had not confirmed an active investigation. They had not stated whether Dr. Okonkwo, the regional director, would attend the sponsor governance committee.

A confidential complaint to BIMO does not require the agency to notify the CRO in advance. I did not know if next Wednesday would be a standard presentation, a quiet postponement, or a federal intervention.

I walked back to my office. The white Q3 binder was sitting on my desk.

I was still scheduled to co-present in nine days.

I woke up my computer. I opened a blank document. I started writing the monitoring-oversight summary I was actually going to present. Real audit trails. Real site notes. Real deletions.

At 1:00 PM, an hour before the meeting, I stood in my office. I held the white Q3 binder. I checked the alignment of the heavy paper pages. I checked the adhesive on the sticky note I had placed on the August tab. I closed the cover. I packed it into my leather work bag.

At 1:45 PM, I walked into the sponsor governance committee meeting room. The room was located on the executive floor of the CRO headquarters. A long oak table dominated the center of the space. The heavy leather chairs were arranged with precise geometry. At the far end of the room, a digital projector was already running. It cast a solid blue standby screen against the white wall.

I walked to my assigned seat. It was directly to the left of the presenter’s wooden lectern. I unzipped my bag. I pulled out the white QA – Phase 3 Q3 binder. I set it flat on the table in front of me.

The committee members began to arrive. The sponsor’s Chief Medical Officer entered first. He took his seat at the head of the oak table. The principal investigator network lead followed, taking the chair to his right.

The Institutional Review Board chair arrived a moment later. She sat next to the investigator. Three institutional executives entered together and occupied the middle seats on the opposite side of the table.

Each of them carried a thick, spiral-bound committee binder. The binders contained the slide decks Patrice had curated. They contained the aggregated metrics, the smoothed safety data, and the flawless monitoring summaries. The executives set their binders on the wood. They opened them to the title page.

There was one additional chair positioned at the far end of the table, near the windows. A man I had never met in person was sitting in it. He wore a dark suit. A visitor’s badge hung from a lanyard around his neck. He was reading a document on a digital tablet.

I knew who he was. I knew his title. I had addressed the BIMO complaint to him nine days ago. He was Dr. Okonkwo. He was the FDA Bioresearch Monitoring Regional Director for the Northeast.

He had not been on the meeting invite. His presence was not customary. A regional director does not observe a sponsor governance committee meeting unless a federal mechanism has been activated.

At 1:55 PM, Patrice Navarrete walked through the heavy glass doors.

She carried her laptop and a black leather folder. She wore a tailored suit. She did not look at me when she passed my chair. She walked straight to the lectern. She set her laptop down. She plugged in the display cable. She tapped her keyboard.

The first slide of her presentation replaced the blue standby screen on the wall. It displayed the CRO logo and the Phase 3 program title.

At 2:00 PM exactly, the sponsor CMO opened the meeting. He leaned forward. He welcomed the committee members. He thanked the executives for traveling. Then he nodded toward the end of the table.

“Before we begin the trial completion review,” the CMO said, “I want to acknowledge Dr. Okonkwo from the FDA. He requested to observe today’s governance meeting.”

Patrice had been adjusting the angle of her laptop screen. Her hands stopped moving.

She looked down the length of the long oak table. She looked at Dr. Okonkwo. She looked at the CMO.

The pivotal database lock was scheduled for Friday. The multi-million-dollar bonus pool was contingent on that lock. A BIMO regional director appearing unannounced three days before a database lock means one thing in clinical operations. It means a for-cause inspection has been triggered. It means the data is frozen.

Patrice held her position. She did not step back from the lectern. She did not ask why he was there. The pause lasted no more than three seconds.

She resumed adjusting her screen. She clicked her presenter remote.

She started the presentation.

For twenty-five minutes, she ran the meeting exactly as she always had. Her voice was steady. Her cadence was measured. She walked the committee through the enrollment metrics site by site. She summarized the safety adverse-event profiles. She presented the retention data. She controlled the flow of information in the room.

She reached slide five.

She clicked the remote. The header appeared in black text on the wall: Monitoring Oversight Verification – Prior-Period QA.

My name was the only bullet point centered on the screen. Below my name was my clinical quality assurance certification number.

“As we prepare for the Friday database lock,” Patrice said, addressing the CMO directly, “I want to highlight the independence of our monitoring program. Irena Mirescu, our certified clinical QA lead, has verified the compliance record.”

Dr. Okonkwo locked his digital tablet. He placed it flat on the table. The small tap of the casing against the wood echoed in the quiet room.

“Ms. Navarrete,” Dr. Okonkwo said.

Patrice stopped speaking.

“The agency has placed a hold on the Phase 3 database lock,” Dr. Okonkwo said. He did not raise his voice. “An active investigation was opened last week regarding the electronic Trial Master File.”

The room went completely still. The hum of the projector fan was the only sound.

The secondary arc of the timeline resolved in that exact moment. The BIMO complaint was active. The IRB suspension recommendation under 21 CFR 56.113 was now inevitable. The database lock could not proceed. The race against the Friday schedule was over.

Patrice looked at the FDA director.

“We were not informed an FDA BIMO complaint had been opened,” Patrice said. “That is procedurally irregular.”

“A confidential complaint to BIMO does not require advance notice to the CRO,” Dr. Okonkwo said.

Patrice turned her head. She looked down at me from the lectern.

“What did you do?” she asked, quietly.

“I filed an FDA BIMO complaint nine days ago,” I said. I did not match her volume. My voice carried clearly across the table. “I am the QA lead. It is my job.”

Patrice squared her shoulders to the room. She bypassed me completely. She looked directly at the CMO and the IRB chair.

“The deviations were administrative-completeness items consistent with the validated monitoring framework—”

I did not let her finish the sentence. I did not speak about my career, or the framed letter, or the betrayal of my signature. I stated the mechanism.

“For eight consecutive months, eighty-seven informed-consent deviations—including fourteen on participants with cognitive impairment—were entered by my monitors and deleted from the eTMF audit trail between 23:05 and 23:30 each Friday before sponsor Saturday data review,” I said. “The 21 CFR Part 11 hash chain is unedited.”

Patrice put both hands on the outer edges of the lectern. She gripped the wood.

“Administrative-completeness purges are part of the validated process—”

I picked up the white QA – Phase 3 Q3 binder. I reached across the gap and set it open in the center of the oak table. I turned a single page to the August tab.

“August Friday 23:08,” I said. I looked at Patrice. “Subject 4-117 consent-witness-only delete. Bonnie Pryor logged the deviation. Charlene Booker monitored the Atlanta site. You told her to delete on the Friday compactor or lose the database-lock bonus.”

The sponsor Chief Medical Officer had been holding a silver pen over a legal pad. He lowered the pen. He leaned forward in his heavy chair. He lifted the white Q3 binder from the center of the table.

He pulled it toward him. He looked down at the August tab. He read the 23:08 sticky note. He traced the line of text down to my signature at the bottom of the page. He did not look up at Patrice for the next two minutes.

Dr. Okonkwo did not ask to see the binder. He had already read the digital copies I had uploaded. He reached out and closed his thick, spiral-bound committee binder. He set it face-down on the wood. He picked up his phone. He began typing a message with his right thumb. He did not put the phone down.

The Institutional Review Board chair had absolute authority to suspend enrollment under 21 CFR 56.113. She had been taking detailed notes on the safety profiles. When I named the cognitively impaired participants, her hands stopped moving.

She pushed her chair back from the table. The legs scraped against the carpet. The movement was exactly four inches. She looked at the Subject 4-117 slide still projected on the wall. She looked down at the open binder resting in front of the CMO. She did not look at Patrice again.

Patrice stood at the lectern. No one asked her to continue the presentation. No one asked her a single question about the metrics. The CRO operations director was facing an FDA BIMO for-cause inspection with a guaranteed Form 483.

The multi-million-dollar sponsor agreement was breached. A criminal referral under 18 U.S.C. Section 1001 for false statements relating to a federally regulated trial was a mathematical certainty.

She reached out and closed the lid of her laptop. She unplugged the display cable.

The projector screen on the wall reverted to the blue standby screen.

Patrice gathered her presentation materials slowly. She lifted her black leather folder. She squared the edge of the folder against the hard wood of the lectern. She aligned it perfectly.

“I built this CRO’s Phase 3 monitoring program from a four-site operation,” Patrice said. Her voice was flat. “Administrative-completeness purging was always a defensible exercise of process judgment.”

She picked up her laptop. She picked up her folder. She turned away from the table.

She walked toward the heavy glass doors. She left the room without making eye contact with the CMO, the IRB chair, or the FDA director. She walked out into the hallway. The door shut behind her, sealing the quiet back into the room.

Dr. Okonkwo stopped typing on his phone. He picked up his pen. He wrote one line on his legal pad. He noted the time on his record. It was 2:54 PM.